C75

CAT: 0804-HY-12364-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-12364-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM[1][2][3]. C75 is a potent CPT1A activator[5].
CAS Number
[218137-86-1]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Fatty Acid Synthase (FASN)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/C75.html
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(C(C1=C)C(CCCCCCCC)OC1=O)O
Molecular Formula
C14H22O4
Molecular Weight
254.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.|[2]Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+) -C75 is a strong anorectic drug; (-) -C75 has antitumor activity. Chirality. 2013 May;25 (5) :281-7.|[3]Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100 (10) :5628-33.|[4]Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99 (14) :9498-502.|[5] Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105 (3) :550-560.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products